Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.

Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF.

PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.

2.

Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.

Bertazza L, Barollo S, Radu CM, Cavedon E, Simioni P, Faggian D, Plebani M, Pelizzo MR, Rubin B, Boscaro M, Pezzani R, Mian C.

J Cell Mol Med. 2015 Sep;19(9):2244-52. doi: 10.1111/jcmm.12612. Epub 2015 Jun 17.

3.

Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.

Milewska M, Romano D, Herrero A, Guerriero ML, Birtwistle M, Quehenberger F, Hatzl S, Kholodenko BN, Segatto O, Kolch W, Zebisch A.

PLoS One. 2015 Jun 12;10(6):e0129859. doi: 10.1371/journal.pone.0129859. eCollection 2015.

4.

Autophagy in thyroid cancer: present knowledge and future perspectives.

Netea-Maier RT, Klück V, Plantinga TS, Smit JW.

Front Endocrinol (Lausanne). 2015 Feb 18;6:22. doi: 10.3389/fendo.2015.00022. eCollection 2015. Review.

5.

A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth.

Plews RL, Mohd Yusof A, Wang C, Saji M, Zhang X, Chen CS, Ringel MD, Phay JE.

J Clin Endocrinol Metab. 2015 May;100(5):E748-56. doi: 10.1210/jc.2014-1777. Epub 2015 Feb 24.

6.

Advances in thyroid cancer treatment: latest evidence and clinical potential.

Alonso-Gordoa T, Díez JJ, Durán M, Grande E.

Ther Adv Med Oncol. 2015 Jan;7(1):22-38. doi: 10.1177/1758834014551936. Review.

7.

Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer.

Yun KJ, Kim W, Kim EH, Kim MH, Lim DJ, Kang MI, Cha BY.

Endocrinol Metab (Seoul). 2014 Sep;29(3):388-93. doi: 10.3803/EnM.2014.29.3.388. Epub 2014 Sep 25.

8.

Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Malaguarnera R, Chen KY, Kim TY, Dominguez JM, Voza F, Ouyang B, Vundavalli SK, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2014 Oct;99(10):E1976-87. doi: 10.1210/jc.2013-3976. Epub 2014 Jul 16.

9.

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.

McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):E1600-9. doi: 10.1073/pnas.1404357111. Epub 2014 Apr 7.

10.

mTOR pathway in colorectal cancer: an update.

Francipane MG, Lagasse E.

Oncotarget. 2014 Jan 15;5(1):49-66. Review.

11.

Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.

Lin SF, Lin JD, Chou TC, Huang YY, Wong RJ.

PLoS One. 2013 Oct 14;8(10):e77684. doi: 10.1371/journal.pone.0077684. eCollection 2013.

12.

Genetics and epigenetics of sporadic thyroid cancer.

Vu-Phan D, Koenig RJ.

Mol Cell Endocrinol. 2014 Apr 5;386(1-2):55-66. doi: 10.1016/j.mce.2013.07.030. Epub 2013 Aug 8. Review.

13.

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.

Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA.

Endocr Relat Cancer. 2013 Aug 21;20(5):659-67. doi: 10.1530/ERC-13-0085. Print 2013 Oct.

14.

B-Raf and the inhibitors: from bench to bedside.

Huang T, Karsy M, Zhuge J, Zhong M, Liu D.

J Hematol Oncol. 2013 Apr 25;6:30. doi: 10.1186/1756-8722-6-30. Review.

15.

Evolving approaches to patients with advanced differentiated thyroid cancer.

Haugen BR, Sherman SI.

Endocr Rev. 2013 Jun;34(3):439-55. doi: 10.1210/er.2012-1038. Epub 2013 Apr 10. Review. Erratum in: Endocr Rev. 2013 Dec;34(6):925.

16.

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE.

Clin Cancer Res. 2013 May 15;19(10):2688-98. doi: 10.1158/1078-0432.CCR-12-2556. Epub 2013 Apr 2. Erratum in: Clin Cancer Res. 2013 Jul 15;19(14):4018.

17.

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.

Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF.

PLoS One. 2013;8(3):e59879. doi: 10.1371/journal.pone.0059879. Epub 2013 Mar 22.

18.

Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.

Giunti S, Antonelli A, Amorosi A, Santarpia L.

Int J Endocrinol. 2013;2013:803171. doi: 10.1155/2013/803171. Epub 2013 Feb 21.

19.

Molecular pathogenesis and mechanisms of thyroid cancer.

Xing M.

Nat Rev Cancer. 2013 Mar;13(3):184-99. doi: 10.1038/nrc3431. Review.

20.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM.

Oncotarget. 2012 Oct;3(10):1068-111. Review.

Items per page

Supplemental Content

Write to the Help Desk